We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,357
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CISN
2026
DELISTED
Cision Ltd. Ordinary Share
CISN
| $1.12M | ﹤0.01% |
112,159
+931
| +0.8% | +$8.89K |
|
|
TEN
2027
DELISTED
Tenneco Inc. Class A Voting Common Stock
TEN
| $1.11M | ﹤0.01% |
84,983
+1,340
| +2% | +$17.6K |
|
2028
Peabody Energy
BTU
$2.95B
| $1.11M | ﹤0.01% |
121,955
+22
| +0% | +$253 |
|
|
EXPR
2029
DELISTED
Express, Inc.
EXPR
| $1.11M | ﹤0.01% |
11,419
+425
| +4% | +$33.4K |
|
2030
Denali Therapeutics
DNLI
$3.9B
| $1.11M | ﹤0.01% |
63,512
+782
| +1% | +$13K |
|
|
FOCS
2031
DELISTED
Focus Financial Partners Inc. Class A
FOCS
| $1.11M | ﹤0.01% |
37,531
+488
| +1% | +$12.5K |
|
|
DHIL
2032
DELISTED
Diamond Hill
DHIL
| $1.1M | ﹤0.01% |
7,867
-1
| -0% | -$140 |
|
2033
Future Fuel
FF
$227M
| $1.1M | ﹤0.01% |
89,149
+4,937
| +6% | +$58.8K |
|
2034
OneSpaWorld
OSW
$2.69B
| $1.1M | ﹤0.01% |
65,588
+979
| +2% | +$15.4K |
|
|
RVNC
2035
DELISTED
Revance Therapeutics, Inc.
RVNC
| $1.1M | ﹤0.01% |
67,891
+1,237
| +2% | +$19.2K |
|
|
THR
2036
DELISTED
Thermon Group Holdings
THR
| $1.1M | ﹤0.01% |
41,052
+410
| +1% | +$10.3K |
|
|
ACH
2037
Accendra Health
ACH
$230M
| $1.09M | ﹤0.01% |
211,433
+10,299
| +5% | +$66.1K |
|
|
CAMP
2038
DELISTED
CalAmp Corp.
CAMP
| $1.09M | ﹤0.01% |
4,955
+263
| +6% | +$64.1K |
|
2039
Cardlytics
CDLX
$24.2M
| $1.08M | ﹤0.01% |
1,717
+281
| +20% | +$137K |
|
|
BRSL
2040
Brightstar Lottery PLC
BRSL
$2.02B
| $1.08M | ﹤0.01% |
71,915
-161
| -0.2% | -$2.29K |
|
2041
BellRing Brands
BRBR
$1.41B
| $1.08M | ﹤0.01% |
+50,556
| New | +$990K |
|
2042
Manitowoc
MTW
$522M
| $1.08M | ﹤0.01% |
61,479
+440
| +0.7% | +$6.42K |
|
2043
Prothena Corp
PRTA
$443M
| $1.07M | ﹤0.01% |
67,573
+2,213
| +3% | +$23.7K |
|
2044
Nordic American Tanker
NAT
$1.35B
| $1.07M | ﹤0.01% |
217,332
+333
| +0.2% | +$1.27K |
|
2045
Gorman-Rupp
GRC
$2.26B
| $1.07M | ﹤0.01% |
28,483
+267
| +0.9% | +$9.72K |
|
|
IMGN
2046
DELISTED
Immunogen Inc
IMGN
| $1.07M | ﹤0.01% |
208,965
+2,542
| +1% | +$8.63K |
|
|
CORR
2047
DELISTED
CorEnergy Infrastructure Trust, Inc.
CORR
| $1.07M | ﹤0.01% |
23,853
+1,787
| +8% | +$81.2K |
|
|
DSPG
2048
DELISTED
DSP Group Inc
DSPG
| $1.07M | ﹤0.01% |
67,722
+3,974
| +6% | +$58.5K |
|
2049
Omeros
OMER
$927M
| $1.06M | ﹤0.01% |
75,482
+622
| +0.8% | +$9.11K |
|
|
HMHC
2050
DELISTED
Houghton Mifflin Harcourt Company
HMHC
| $1.06M | ﹤0.01% |
170,148
+1,501
| +0.9% | +$8.76K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.